A high-throughput assay for connexin 43 (Cx43, GJA1) gap junctions using codon-optimized aequorin

Assay and Drug Development Technologies

Volumn 11, Issue 2, 2013, Pages 93-100

  Haq, Nazia ^a   Grose, David ^a   Ward, Emma ^a   Chiu, Oiyee ^a   Tigue, Natalie ^a   Dowell, Simon J ^a   Powell, Andrew J ^a   Chen, Mao Xiang ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

18ALPHA GLYCYRRHETINIC ACID; ADRENALIN; AEQUORIN; ALPHA 1A ADRENERGIC RECEPTOR; CALCEIN; CALCIUM; CAPSAICIN; CODON OPTIMIZED AEQUORIN; CONNEXIN 43; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ARTICLE; CELL POPULATION; CHEMICAL PROCEDURES; CODON OPTIMIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; FLOW CYTOMETRY; GAP JUNCTION; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INCUBATION TIME; ION PERMEABILITY; LUMINESCENCE; MITOCHONDRION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

AEQUORIN; BIOLOGICAL ASSAY; CALCIUM; CALCIUM SIGNALING; CELL SEPARATION; CODON; CONNEXIN 43; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; FLOW CYTOMETRY; FLOW INJECTION ANALYSIS; HELA CELLS; HUMANS; ION CHANNEL GATING; LUMINESCENT AGENTS;

EID: 84874899152     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2012.469     Document Type: Article

References (33)

1. Suga M, Maeda S, Nakagawa S, Yamashita E, Tsukihara T: A description of the structural determination procedures of a gap junction channel at 3.5 A resolution. Acta Crystallogr D Biol Crystallogr 2009;65:758-766.
2. Rackauskas M, Neverauskas V, Skeberdis V: Diversity and properties of connexin gap junction channels. Medicina (Kaunas) 2010;46:1-12.
3. Reaume A, de Sousa P, Kulkarni S, et al.: Cardiac malformation in neonatal mice lacking connexin43. Science 1995;267:1831-1834.
4. Guerroro P, Schuessler R, Davis L, et al.: Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J Clin Invest 1997;99:1991-1998. (Pubitemid 27175947)
5. Gutstein D, Morley G, Tamaddon H, et al.: Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 2001;88:333-339. (Pubitemid 32173758)
6. Poelzing S, Akar F, Baron E, et al.: Heterogeneous connexin43 expression produces electrophysiological heterogeneities across ventricular wall. Am J Physiol Heart Circ Physiol 2004;286:H2001-H2009. (Pubitemid 38525492)
7. Poelzing S, Rosenbaum D: Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol 2004;287:H1762-H1770. (Pubitemid 39313284)
8. Koppelhus U, Tranebjaerg L, Esberg G, et al.: A novel mutation in the connexin 26 gene (GJB2) in a child with clinical and histological features of keratitisichthyosis-deafness (KID) syndrome. Clin Exp Dermatol 2011;36:142-148.
9. Meggouh F, Benomar A, Rouger H, et al.: The first de novo mutation of the connexin 32 gene associated with X linked Charcot-Marie-Tooth disease. J Med Genet 1998;35:251-252. (Pubitemid 128769206)
10. Bonendiek S, Raman G: Connexin modulators and their potential targets under the magnifying glass. Curr Med Chem 2010;17:4191-4230.
11. De Vuyst E, Boengler K, Antoons G, Sipido K, Schulz R, Leybaert L: Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol 2011;163:469-483.
12. Dhein S, Hagen A, Jozwiak J, et al.: Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrythmic peptides. Naunyn Schmiedebergs Arch Pharmacol 2009;381:221-234.
13. Rossman E, Liu K, Morgan G, et al.: The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther 2009;329:1127-1133.
14. Butera J, Larsen B, Hennan J, et al.: Discovery of (2S,4R)-1-(2- aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation. J Med Chem 2009;52:908-911.
15. Hawat G, Benderdour M, Rousseau G, Baroudi G: Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury. Pflugers Arch Eur J Physiol 2010;60:583-592.
16. Silberstein S, Schoenen J, Gö bel H, et al.: Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia 2009;29:17-27.
17. Beck P, Odle A, Wallace-Huitt T, Skinner R, Garcia-Rill E: Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep 2008;31:647-654.
18. Patel S, Milwid J, King K, et al.: Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol 2012;30:179-183.
19. Bedner P, Niessen H, Odermatt B, Kretz M, Willecke K, Harz H: Selective permeability of different connexin channels to the second messenger cyclic AMP. J Biol Chem 2006;281:6673-6681. (Pubitemid 43847602)
20. Lin G, Rurangirwa J, Koval M, Steinberg T: Gap junctional communication modulates agonist-induced calcium oscillations in transfected HeLa cells. J Cell Sci 2004;117:881-887. (Pubitemid 38386945)
21. Lurtz M, Louis C: Intracellular calcium regulation of connexin43. Am J Physiol Cell Physiol 2007;293:1806-1813.
22. Li Z, Yan Y, Powers E, et al.: Identification of gap junction blockers using automated fluorescence microscopy imaging. J Biomol Screen 2003;8: 489-499.
23. Chen S, Lee L: Non-invasive microfluidic gap junction assay. Integr Biol (Camb) 2010;2:130-138.
24. Ye N, Bathany C, Hua S: Assay for molecular transport across gap junction channels in one-dimensional cell arrays. Lab Chip 2011;11:1096-1101.
25. Stables J, Green A, Marshall F, et al.: A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. Anal Biochem 1997;252: 115-126. (Pubitemid 27408700)
26. Condreay J, Witherspoon S, Clay W, Kost T: Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA 1999;96:127-132. (Pubitemid 29036064)
27. Salameh A: Life cycle of connexins: regulation of connexin synthesis and degradation. Adv Cardiol 2006;42:57-70. (Pubitemid 43805857)
28. Brough SJ, Shah P: Use of aequorin for G protein-coupled receptor hit identification and compound profiling. Methods Mol Biol 2009;552: 181-198.
29. Vernon W, Printen J: Assay for intracellular calcium using a codon-optimized aequorin. BioTechniques 2002;33:730-734. (Pubitemid 35168052)
30. Brini M, Marsault R, Bastianutto C, Alvarez J, Pozzan T, Rizzuto R: Transfected aequorin in the measurement of cytosolic Ca2+ concentration ([Ca2+[c). A critical evaluation. J Biol Chem 1995;270:9896-9903.
31. Abdel-Latif A: Calcium-mobilizing receptors, polyphosphoinositides, generation of second messengers and contraction in the mammalian iris smooth muscle: historical perspectives and current status. Life Sci 1989;45:757-786. (Pubitemid 19202512)
32. George C, Kendall J, Campbell A, Evans W: Connexin-aequorin chimerae report cytoplasmic calcium environments along trafficking pathways leading to gap junction biogenesis in living COS-7 cells. J Biol Chem 1998;273:29822-29829. (Pubitemid 28509996)
33. Harris A: Connexin channel permeability to cytoplasmic molecules. Prog Biophys Mol Biol 2007;94:120-143. (Pubitemid 46782979)